Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		Phase III Randomized, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Subjects to Compare the Efficacy of AZD2171 [RECENTIN] Monotherapy and the Combination of AZD2171 with Lomustine to the Efficacy of Lomustine Alone

		Phase:		Phase 3

		Treatment ID#:		1907

		Age Group:		Adults Only

		Min Karnofsky Score:		70: Cares for self, unable to perform normal activity or to do active work

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Recurrent GBM > 17 yrs. Measurable disease or prior resection. Must have received only one prior chemotherapy regimen and must contain Temodar. Gliadel wafers are permitted.

		Last Updated:		04/06/2009

		Tumor Types:		Glioblastoma Multiforme


		Comments:

		Treatment Type:		Chemotherapy

		Contact:		Alison Kastl BS Director of Clinical Trials UC Brain Tumor Center 234 Goodman Street Cincinnati, OH 45219 USA Phone: 513-584-7698 Fax: 513-584-5680 E-mail: kastla@ucmail.uc.edu Website: ucbraintumorcenter.com

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By